Moran Wealth Management’s Quest Diagnostics DGX Stock Holding History

Moran Wealth Management’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22.1M	Sell	104,495 -3,856	-4%	-$757K	0.6%	38
2026 Q1	$21.2M	Buy	108,351 +4,287	+4%	+$833K	0.65%	34
2025 Q4	$18.1M	Sell	104,064 -1,087	-1%	-$198K	0.55%	48
2025 Q3	$20M	Buy	105,151 +1,840	+2%	+$327K	0.6%	43
2025 Q2	$18.6M	Buy	+103,311	New	+$17.9M	0.57%	48
2023 Q3	–	Sell	-4,770	Closed	-$670K	–	379
2023 Q2	$670K	Sell	4,770 -6,464	-58%	-$891K	0.03%	291
2023 Q1	$1.59M	Sell	11,234 -122,703	-92%	-$17.6M	0.06%	236
2022 Q4	$21M	Buy	+133,937	New	+$19.2M	0.8%	29

Other funds holding DGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Moran Wealth Management's DGX Position: Q2 2026 in Review

Moran Wealth Management reduced its Quest Diagnostics (DGX) stake by 3.6% in Q2 2026, selling an estimated $757K and leaving 104,495 shares worth $22.1M. The position accounts for 0.6% of the portfolio, ranked #38.

Moran Wealth Management first reported a position in DGX in Q4 2022 and has held it in 8 quarters since. 1,107 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

Moran Wealth Management held 104,495 shares of Quest Diagnostics worth $22.1M as of Q2 2026.
Moran Wealth Management sold 3,856 Quest Diagnostics shares in Q2 2026, an estimated $757K.
Quest Diagnostics made up 0.6% of Moran Wealth Management's portfolio in Q2 2026, its #38 holding.
Moran Wealth Management first reported a position in Quest Diagnostics in Q4 2022 and has held it in 8 quarters since.
1,107 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Moran Wealth Management's 13F filing for Q2 2026, filed 5 Aug 2026.